Medartis Valuation Multiples

Medartis is valued at $1.2B as of October 2026, a 3.7x revenue multiple. In the last 12 months, Medartis revenue was $390M and Medartis EBITDA was $70M.

Medartis Overview

About Medartis

Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from EMEA and also has a presence in APAC, LATAM, and USA.


Founded

1997

HQ

Switzerland

Employees

949

Financials (LTM)

Revenue: $390M
EBITDA: $70M

EV

$1.5B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Medartis Financials

Medartis reported last 12-month revenue of $390M and EBITDA of $70M.

In the same LTM period, Medartis generated $317M in gross profit, $70M in EBITDA, and $17M in net income.

Revenue (LTM)


Medartis P&L

In the most recent fiscal year, Medartis reported revenue of $324M and EBITDA of $53M.

Medartis is profitable as of last fiscal year, with gross margin of 76%, EBITDA margin of 16%, and net margin of 3%.

See analyst estimates for Medartis
LTMLast FY202320242025202620272028
Revenue$390M$324M$261M$276M$324M
Gross Profit$317M$246M$206M$220M$246M
Gross Margin81%76%79%79%76%
EBITDA$70M$53M$31M$37M$53M
EBITDA Margin18%16%12%13%16%
EBIT Margin8%1%5%3%1%
Net Profit$17M$10M$761K$4M$10M
Net Margin4%3%0%2%3%
Net Debt-$127M---

Financial data powered by Morningstar, Inc.

Medartis Stock Performance

Medartis has current market cap of $1.2B, and enterprise value of $1.5B.

Market Cap Evolution


Medartis' stock price is $99.20.

Medartis share price decreased by 1.8% in the last 30 days, and by 2.4% in the last year.

Medartis has an EPS (earnings per share) of $0.81.

See more trading valuation data for Medartis
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1.5B$1.2B-0.5%-1.8%-9.0%-2.4%$0.81

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Medartis Valuation Multiples

Medartis trades at 3.7x EV/Revenue multiple, and 20.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Medartis

EV / Revenue (LTM)


Medartis Financial Valuation Multiples

As of October 8, 2026, Medartis has market cap of $1.2B and EV of $1.5B.

Medartis has a P/E ratio of 73.8x.

LTMLast FY202320242025202620272028
EV/Revenue3.7x4.5x5.6x5.3x4.5x
EV/EBITDA20.8x27.2x46.6x39.2x27.2x
EV/EBIT44.0xn/m122.1x163.5xn/m
EV/Gross Profit4.6x5.9x7.1x6.6x5.9x
P/E73.8x123.0xn/mn/m123.0x
EV/FCFn/m246.7xn/m56.3x246.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Medartis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Medartis Margins & Growth Rates

Medartis grew revenue by 25% and EBITDA by 38% in the last fiscal year.

In the most recent fiscal year, Medartis reported gross margin of 76%, EBITDA margin of 16%, and net margin of 3%.

See estimated margins and future growth rates for Medartis

Medartis Margins

Last FY202420252026202720282029
Gross Margin76%79%76%83%
EBITDA Margin16%13%16%18%
EBIT Margin1%3%1%9%
Net Margin3%2%3%5%
FCF Margin2%9%2%(0%)

Medartis Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth25%6%17%25%
Gross Profit Growth36%7%12%36%
EBITDA Growth38%19%44%38%
EBIT Growth1513%(25%)(74%)1513%
Net Profit Growth103%470%131%103%
FCF Growth(118%)1690%(77%)(118%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Medartis Operational KPIs

Medartis' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.

Medartis' Rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medartis' Rule of X is 80% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Medartis
LTMLast FY202320242025202620272028
Rule of 4036%43%---
Bessemer Rule of X62%80%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue45%48%46%45%48%
G&A Expenses to Revenue18%17%16%17%17%
R&D Expenses to Revenue10%12%12%19%12%
Opex to Revenue72%75%74%76%75%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Medartis Competitors

Medartis competitors include SonoScape, Vitrolife, MicroPort EP, PHC Holdings, Arcs Co, Shinva, Weigao Group, Alpha Tau Medical, SEEGENE and Conmed.

Most Medartis public comparables operate across Medical Devices, DeepTech and HealthTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
SonoScape$345M$35M3.2x2.9x31.7x25.3x
Vitrolife$343M($440M)3.9x3.8x(3.0x)12.0x
MicroPort EP$69M$13M14.6x12.8x80.9x73.6x
PHC Holdings$2.3B$315M1.1x1.0x7.7x6.7x
Arcs Co$4B$182M0.2x0.2x4.2x4.3x
Shinva$1.5B$126M0.6x0.6x7.3x7.4x
Weigao Group$227M$56M4.8x4.6x19.4x14.0x
Alpha Tau Medical-($45M)-2261.8x(27.6x)(23.9x)

This data is available for Pro users. Sign up to see all Medartis competitors and their valuation data.

Start Free Trial

Medartis VC Funding History

Before going public, Medartis raised funding across 1 round.


Medartis Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Dec-17Undisclosed stageEndeavour Vision--Endeavour Vision took a minority stake in Medartis, the Basel manufacturer of internal fixation systems for small bone and extremity surgery. The investment was made through pre-IPO convertible loans issued in December 2017, which converted into ordinary shares in parallel with the company's listing on the SIX Swiss Exchange in March 2018. Endeavour Vision came out of the listing as one of Medartis' larger shareholders, holding roughly 6.5% of the company. Neither party disclosed the size of the individual commitment.

Acquisitions by Medartis

Medartis has acquired 4 companies to date.

Last acquisition by Medartis was on September 17th 2026. Medartis acquired Miami Anatomical Research Center for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Medartis

Miami Anatomical Research Center
Keri Medical
Nextremity Solutions
Mimedis
Description
Miami Anatomical Research Center is a research institute that conducts clinical research studies.
Keri Medical is a Lyon, France-based orthopedics firm manufacturing specialized implants and instruments for hand and wrist surgery. Its product line includes plates, screws, and anchors used in trauma repair, arthritis treatment, and reconstructive procedures by surgeons worldwide.
-
Mimedis is a Basel, Switzerland-headquartered medical device company specializing in patient-specific cranial and orthopedic implants using 3D printing and biomaterials. Spun out from FHNW and University Hospital Basel in 2013, it produces custom titanium and PEEK implants for trauma and tumor reconstruction, collaborating with surgeons across Europe.
HQ CountryUnited StatesSwitzerlandUnited StatesSwitzerland
HQ City
Miami, FL
Geneva
-
Basel
Deal Date17 Sep 202617 Jul 20257 Mar 20225 Jul 2017
Valuationundisclosed$211M$70Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Medartis acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Medartis

Medartis has invested in 1 company to date.

Latest investment by Medartis was on March 17th 2023. Medartis invested in Keri Medical in their $19M Strategic investment round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Medartis

Keri Medical
Description
Keri Medical is a Lyon, France-based orthopedics firm manufacturing specialized implants and instruments for hand and wrist surgery. Its product line includes plates, screws, and anchors used in trauma repair, arthritis treatment, and reconstructive procedures by surgeons worldwide.
HQ CountrySwitzerland
HQ City
Geneva
Deal Date17 Mar 2023
RoundStrategic investment
Raised$19M
InvestorsMedartis
Valuation$41M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Medartis investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Medartis

When was Medartis founded?Medartis was founded in 1997.
Where is Medartis headquartered?Medartis is headquartered in Switzerland.
How many employees does Medartis have?As of today, Medartis has over 949 employees.
Is Medartis publicly listed?Yes, Medartis is a public company listed on SIX Swiss Exchange.
What is the stock symbol of Medartis?Medartis trades under MED ticker.
When did Medartis go public?Medartis went public in 2018.
Who are competitors of Medartis?Medartis main competitors include SonoScape, Vitrolife, MicroPort EP, PHC Holdings, Arcs Co, Shinva, Weigao Group, Alpha Tau Medical, SEEGENE, Conmed.
What is the current market cap of Medartis?Medartis' current market cap is $1.2B.
What is the current revenue of Medartis?Medartis' last 12 months revenue is $390M.
What is the current revenue growth of Medartis?Medartis revenue growth (NTM/LTM) is 18%.
What is the current EV/Revenue multiple of Medartis?Current revenue multiple of Medartis is 3.7x.
What is the current EBITDA of Medartis?Medartis' last 12 months EBITDA is $70M.
What is Medartis' EBITDA margin?Medartis' last 12 months EBITDA margin is 18%.
What is the current EV/EBITDA multiple of Medartis?Current EBITDA multiple of Medartis is 20.8x.
What is the current FCF of Medartis?Medartis' last 12 months FCF is $2M.
What is Medartis' FCF margin?Medartis' last 12 months FCF margin is 0%.
What is the current EV/FCF multiple of Medartis?Current FCF multiple of Medartis is 752.8x.
How many companies Medartis has acquired to date?As of October 2026, Medartis has acquired 4 companies.
What was the largest acquisition by Medartis?$211M acquisition of Keri Medical on 17th July 2025 was the largest M&A Medartis has done to date.
What companies Medartis acquired?Medartis acquired Keri Medical, Nextremity Solutions, Miami Anatomical Research Center, and Mimedis.
In how many companies Medartis has invested to date?As of October 2026, Medartis has invested in 1 company.
What was the last Medartis investment?On 17th March 2023 Medartis invested in Keri Medical, participating in a $19M Strategic investment round at $41M valuation.
In what companies Medartis invested in?Medartis invested in Keri Medical.

See public comps similar to Medartis

Lists including Medartis

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial